Meanwhile, the application of HER2 targeted monoclonal antibodies (mAbs) such as pertuzumab or trastuzumab demonstrated a prolonged median overall survival (OS) of 16 months in patients with HER2-overexpressing breast cancer [7]. This evidence concerns the gene ERBB2 and breast carcinoma.